Benzinga's Top #PreMarket Gainers

shares rose 35.24% to $18.00 in pre-market trading after the company obtained rights to develop and commercialize a portfolio of preclinical compounds aimed at treating cancer from TransTech Pharma.

shares gained 22.54% to $1.74 in the pre-market trading session on positive Phase 2 Tivozanib results. Aveo Oncology reported a Q4 loss of $0.27 per share.

shares surged 7.94% to $59.55 in pre-market trading after the company reported upbeat Q4 earnings.

shares climbed 5.03% to $59.90 in pre-market trading after the company reported stronger-than-expected fiscal fourth-quarter results.

gained 1.51% to $16.75 in pre-market trading after the company posted better-than-expected adjusted earnings for the fourth quarter.